Identification of thymidylate synthase as a potential therapeutic target for lung cancer
暂无分享,去创建一个
M. Fukuoka | J. Uchida | I. Okamoto | K. Takezawa | K. Nakagawa | M. Kiniwa | S. Tsukioka
[1] R. Ueda,et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer , 2010, Cancer science.
[2] G. Scagliotti,et al. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung , 2009, Clinical Cancer Research.
[3] N. Saijo,et al. Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] Jia Liu,et al. Cyclin E Is Stabilized in Response to Replication Fork Barriers Leading to Prolonged S Phase Arrest* , 2009, The Journal of Biological Chemistry.
[5] Nick Thatcher,et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Thimmapaya,et al. c-Myc-induced Aberrant DNA Synthesis and Activation of DNA Damage Response in p300 Knockdown Cells* , 2009, Journal of Biological Chemistry.
[7] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[8] S. Miyoshi,et al. Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. , 2008, Japanese journal of clinical oncology.
[9] J. Meléndez-Zajgla,et al. Role of Smac/DIABLO in cancer progression , 2008, Journal of experimental & clinical cancer research : CR.
[10] M. Jahanzeb,et al. Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions. , 2008, Clinical lung cancer.
[11] S. Kern,et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward? , 2008, Cancer biology & therapy.
[12] E. Giovannetti,et al. Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells , 2008, Molecular Pharmacology.
[13] D. Zhuang,et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle , 2008, Oncogene.
[14] Kenji Eguchi,et al. A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] R. Sclafani,et al. Cell cycle regulation of DNA replication. , 2007, Annual review of genetics.
[16] L. Zhang,et al. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events , 2007, Oncogene.
[17] G. Scagliotti,et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.
[18] M. Fukushima,et al. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma , 2006, Molecular Cancer Therapeutics.
[19] T. Mori,et al. Differential apoptotic pathways in human keratinocyte HaCaT cells exposed to UVB and UVC , 2005, Apoptosis.
[20] R. Ueda,et al. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. , 2005, Lung cancer.
[21] Maria Paola Costi,et al. Thymidylate synthase structure, function and implication in drug discovery. , 2005, Current medicinal chemistry.
[22] N. Saijo,et al. Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib , 2005, International journal of cancer.
[23] P. Jeggo,et al. ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation , 2004, Cancer Research.
[24] F. Kaye,et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. , 2004, Cancer cell.
[25] N. Cheong,et al. Inhibitor of Apoptosis Proteins Are Substrates for the Mitochondrial Serine Protease Omi/HtrA2* , 2003, Journal of Biological Chemistry.
[26] P. Catalano,et al. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Peters,et al. High-Dose 5-Fluorouracil with Uridine-Diphosphoglucose Rescue Increases Thymidylate Synthase Inhibition but Not 5-Fluorouracil Incorporation into RNA in Murine Tumors , 2002, Oncology.
[28] B. Pfeiffer,et al. Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. , 2001, Molecular pharmacology.
[29] Michael M. Murphy,et al. ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.
[30] M. Spitz,et al. γ-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer , 2001 .
[31] A. Arai,et al. The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor clustering. , 2001, Molecular pharmacology.
[32] H. Tsai,et al. Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment. , 2001, Molecular pharmacology.
[33] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[34] A. Almasan,et al. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells , 2000, Oncogene.
[35] S. Elledge,et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.
[36] N. Dean,et al. Antisense down‐regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5‐FUdR, 5‐FU and Tomudex in HeLa cells , 1999, British journal of pharmacology.
[37] G. Peters,et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[39] G. Peters,et al. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. , 1997, Biochemical pharmacology.
[40] C. Morton,et al. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. , 1993, Cancer research.
[41] P. Carlson,et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. , 1993, Cancer research.
[42] A. Harris,et al. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. , 1991, Cancer research.
[43] L. Bernstein,et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. , 1984, Cancer research.
[44] M. Spitz,et al. Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. , 2001, Cancer research.
[45] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[46] D. Santi,et al. The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.